Although early allograft dysfunction (EAD) negatively impacts on survival from the first months following liver transplantation (LT), direct-acting antivirals (DAAs) have revolutionized HCV therapy. We investigated the EAD definition best predicting 90-day graft loss and identified EAD risk factors in HCV positive recipients. From 11-2002 to 06-2016, 603 HCV-positive patients (hepatocellular carcinoma 53.4%) underwent a first LT with HCV-negative donors. Median recipient MELD score 15, median donor age 63 years. At LT, 77 (12.8%) patients were HCV RNA negative; negativization was achieved and maintained by pre-LT antiviral therapy (61 patients) or pre-LT+pre-emptive post-LT course (16 patients); 60 (77.9%) patients received DAAs and 17 (22.1%) interferon. We compared three different EAD definitions: a) bilirubin≥10 mg/dL or INR≥1.6 on day 7 post-LT or AST or ALT>2000 IU/L within 7 days of LT; b) bilirubin>10 mg/dL on days 2 to 7 post-LT; c) MELD≥19 on day 5 post-LT. EAD defined by MELD≥19 on day 5 post-LT had the lowest negative (0.1) and the highest positive (1.9) likelihood ratio to predict 90-day graft loss. At 90 days post-LT, 9.2% of recipients with EAD lost their graft as opposed to 0.7% of those without EAD (p<0.001). At multivariate analysis, considering variables available at LT, MELD at LT>25 (OR=7.4) or 15-25 (OR=3.2), graft macrovesicular steatosis≥30% (OR=6.7), HCV RNA positive at LT (OR=2.7), donor age>70 years (OR=2.0), earlier LT era (OR=1.8), cold ischemia time≥8 hours (OR=1.8) were significant risk factors for EAD.

Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C recipients

MARTINI, Silvia;TANDOI, FRANCESCO;STRONA, Silvia;SACCO, Marco;MAIONE, FRANCESCA;GONELLA, FEDERICA;STRIGNANO, Paolo;SALIZZONI, Mauro;SARACCO, Giorgio Maria;ROMAGNOLI, Renato
Last
2017

Abstract

Although early allograft dysfunction (EAD) negatively impacts on survival from the first months following liver transplantation (LT), direct-acting antivirals (DAAs) have revolutionized HCV therapy. We investigated the EAD definition best predicting 90-day graft loss and identified EAD risk factors in HCV positive recipients. From 11-2002 to 06-2016, 603 HCV-positive patients (hepatocellular carcinoma 53.4%) underwent a first LT with HCV-negative donors. Median recipient MELD score 15, median donor age 63 years. At LT, 77 (12.8%) patients were HCV RNA negative; negativization was achieved and maintained by pre-LT antiviral therapy (61 patients) or pre-LT+pre-emptive post-LT course (16 patients); 60 (77.9%) patients received DAAs and 17 (22.1%) interferon. We compared three different EAD definitions: a) bilirubin≥10 mg/dL or INR≥1.6 on day 7 post-LT or AST or ALT>2000 IU/L within 7 days of LT; b) bilirubin>10 mg/dL on days 2 to 7 post-LT; c) MELD≥19 on day 5 post-LT. EAD defined by MELD≥19 on day 5 post-LT had the lowest negative (0.1) and the highest positive (1.9) likelihood ratio to predict 90-day graft loss. At 90 days post-LT, 9.2% of recipients with EAD lost their graft as opposed to 0.7% of those without EAD (p<0.001). At multivariate analysis, considering variables available at LT, MELD at LT>25 (OR=7.4) or 15-25 (OR=3.2), graft macrovesicular steatosis≥30% (OR=6.7), HCV RNA positive at LT (OR=2.7), donor age>70 years (OR=2.0), earlier LT era (OR=1.8), cold ischemia time≥8 hours (OR=1.8) were significant risk factors for EAD.
23
915
924
90-day survival; HCV RNA status; direct-acting antivirals; early graft dysfunction; timing of anti-HCV therapy
Martini, Silvia; Tandoi, Francesco; Terzi di Bergamo, Lodovico; Strona, Silvia; Lavezzo, Bruna; Sacco, Marco; Maione, Francesca; Gonella, Federica; Strignano, Paolo; Dell Olio, Dominic; Salizzoni, Mauro; Saracco, Giorgio Maria; Romagnoli, Renato
File in questo prodotto:
File Dimensione Formato  
Articolo Martini.pdf

Accesso aperto

Descrizione: Articolo principale
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 420.68 kB
Formato Adobe PDF
420.68 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1644432
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact